 The primary goals of this trial are 1 to determine the sensitivity and specificity of the CTA spot sign for predicting hematoma growth; 2 to determine the feasibility of using CTA to identify individuals with ICH who are at high risk of hematoma growth and to select study participants for randomization to treatment with rFVIIa or placebo; and 3 to determine the rate of hematoma growth among spot-positive individuals at 24 hourscomparing individuals treated with rFVIIa to those treated with placebo. 